162 related articles for article (PubMed ID: 27902930)
1. Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?
Biglino G; Caputo M; Rajakaruna C; Angelini G; van Rooij E; Emanueli C
Pharmacol Ther; 2017 Feb; 170():192-204. PubMed ID: 27902930
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept.
Halle B; Marcusson EG; Aaberg-Jessen C; Jensen SS; Meyer M; Schulz MK; Andersen C; Kristensen BW
J Neurooncol; 2016 Jan; 126(1):47-55. PubMed ID: 26428358
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Cell Type-Specific Effects of MicroRNA-92a Provides Novel Insights Into Target Regulation and Mechanism of Action.
Rogg EM; Abplanalp WT; Bischof C; John D; Schulz MH; Krishnan J; Fischer A; Poluzzi C; Schaefer L; Bonauer A; Zeiher AM; Dimmeler S
Circulation; 2018 Nov; 138(22):2545-2558. PubMed ID: 30571345
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound and Microbubble-targeted Delivery of a microRNA Inhibitor to the Heart Suppresses Cardiac Hypertrophy and Preserves Cardiac Function.
Kopechek JA; McTiernan CF; Chen X; Zhu J; Mburu M; Feroze R; Whitehurst DA; Lavery L; Cyriac J; Villanueva FS
Theranostics; 2019; 9(23):7088-7098. PubMed ID: 31660088
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
[TBL] [Abstract][Full Text] [Related]
6. Analysis of extracellular vesicle miRNA profiles in heart failure.
Oh JG; Lee P; Gordon RE; Sahoo S; Kho C; Jeong D
J Cell Mol Med; 2020 Jul; 24(13):7214-7227. PubMed ID: 32485073
[TBL] [Abstract][Full Text] [Related]
7. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents.
Torres AG; Threlfall RN; Gait MJ
Artif DNA PNA XNA; 2011; 2(3):71-8. PubMed ID: 22567190
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different chemically modified inhibitors of miR-199b in vivo.
Duygu B; Juni R; Ottaviani L; Bitsch N; Wit JBM; de Windt LJ; da Costa Martins PA
Biochem Pharmacol; 2019 Jan; 159():106-115. PubMed ID: 30452907
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.
Raue R; Frank AC; Syed SN; Brüne B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672261
[TBL] [Abstract][Full Text] [Related]
10. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review.
Navickas R; Gal D; Laucevičius A; Taparauskaitė A; Zdanytė M; Holvoet P
Cardiovasc Res; 2016 Sep; 111(4):322-37. PubMed ID: 27357636
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma.
Kunz M; Brandl M; Bhattacharya A; Nobereit-Siegel L; Ewe A; Weirauch U; Hering D; Reinert A; Kalwa H; Guzman J; Weigelt K; Wach S; Taubert H; Aigner A
J Nanobiotechnology; 2020 Nov; 18(1):173. PubMed ID: 33228711
[TBL] [Abstract][Full Text] [Related]
12. Coronary Artery-Bypass-Graft Surgery Increases the Plasma Concentration of Exosomes Carrying a Cargo of Cardiac MicroRNAs: An Example of Exosome Trafficking Out of the Human Heart with Potential for Cardiac Biomarker Discovery.
Emanueli C; Shearn AI; Laftah A; Fiorentino F; Reeves BC; Beltrami C; Mumford A; Clayton A; Gurney M; Shantikumar S; Angelini GD
PLoS One; 2016; 11(4):e0154274. PubMed ID: 27128471
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease.
Martinez EC; Lilyanna S; Wang P; Vardy LA; Jiang X; Armugam A; Jeyaseelan K; Richards AM
J Mol Cell Cardiol; 2017 Nov; 112():27-39. PubMed ID: 28865712
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.
Gomez IG; Nakagawa N; Duffield JS
Am J Physiol Renal Physiol; 2016 May; 310(10):F931-44. PubMed ID: 26911854
[TBL] [Abstract][Full Text] [Related]
15. Silencing microRNA by interfering nanoparticles in mice.
Su J; Baigude H; McCarroll J; Rana TM
Nucleic Acids Res; 2011 Mar; 39(6):e38. PubMed ID: 21212128
[TBL] [Abstract][Full Text] [Related]
16. Identification of cell and disease specific microRNAs in glomerular pathologies.
Müller-Deile J; Dannenberg J; Liu P; Lorenzen J; Nyström J; Thum T; Schiffer M
J Cell Mol Med; 2019 Jun; 23(6):3927-3939. PubMed ID: 30950172
[TBL] [Abstract][Full Text] [Related]
17. Identification of microRNAs as potential cellular monocytic biomarkers in the early phase of myocardial infarction: a pilot study.
Parahuleva MS; Euler G; Mardini A; Parviz B; Schieffer B; Schulz R; Aslam M
Sci Rep; 2017 Nov; 7(1):15974. PubMed ID: 29162889
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs in cardiovascular disease.
Gurha P
Curr Opin Cardiol; 2016 May; 31(3):249-54. PubMed ID: 26885771
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome-wide based identification of miRs in congenital anomalies of the kidney and urinary tract (CAKUT) in children: the significant upregulation of tissue miR-144 expression.
Jovanovic I; Zivkovic M; Kostic M; Krstic Z; Djuric T; Kolic I; Alavantic D; Stankovic A
J Transl Med; 2016 Jun; 14(1):193. PubMed ID: 27364533
[TBL] [Abstract][Full Text] [Related]
20. MiR-27a ameliorates inflammatory damage to the blood-spinal cord barrier after spinal cord ischemia: reperfusion injury in rats by downregulating TICAM-2 of the TLR4 signaling pathway.
Li XQ; Lv HW; Wang ZL; Tan WF; Fang B; Ma H
J Neuroinflammation; 2015 Feb; 12():25. PubMed ID: 25876455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
